India’s healthcare stakeholders — including hospitals, diagnostic chains, medical device firms, insurers and pharma groups — have responded positively to the rollout of GST 2.0, saying the tax changes announced under Prime Minister Narendra Modi’s leadership will alleviate cost pressures, expand access, and give a strong impulse to domestic manufacturing in health technology.

The revised GST regime, effective September 22, 2025, reduces or rationalizes the tax burden on many essential medicines, medical devices and diagnostics (moving many to a 5 % slab or exempting them), and completely exempts individual health and life insurance premiums. The industry says these moves will lower out-of-pocket expenditure and strengthen the viability of local production.

Industry & Spokesperson Reactions — Optimism, Caution & Commitment
Rajiv Nath, Managing Director, Hindustan Syringes & Medical Devices

“We are highly motivated by PM Modi ji’s address, urging manufacturers to aim for Atmanirbhar Bharat. At Hindustan Syringes & Medical Devices, we share his vision and the hope of a simplified tax regime. Already, during COVID times, we validated our self-reliance — we not only met India’s syringe needs but also exported over 2 billion AD syringes globally.

“These GST reforms must now help unblock working capital — currently, GST paid on services and capital expenditure is not always refunded. We hope our global competitiveness is not hampered by constraints on material imports (such as stainless steel strip) which downstream manufacturers still depend upon.

“Recently, we launched DispoVan dental needles, previously entirely import-dependent, and are scaling up insulin pen needle lines. Our pricing is nearly half prevailing market rates, making access more affordable.”

Nikhil Chopra, Chief Business Officer, Medi Assist

“The recent GST exemption for individual health insurance marks a landmark shift — it lowers the barrier to coverage for millions of Indians.

“However, with group medical cover (GMC) premiums still attracting 18 % GST in many cases, small businesses remain under strain when designing employee benefits. To manage this, enterprises may adopt hybrid models combining retail plans and group schemes.

“The evolving environment will require insurers and TPAs to lean further into technology, digital claims, and flexible product design to sustain expansion of benefits over time.”

Rajiv Nath / AiMeD (Association of Indian Medical Device Industry) — broader industry caution

In a separate but related statement, the Association of Indian Medical Device Industry (AiMeD) urged the government to provide a transition window of 3–6 months to smoothen adjustments in labeling, inventory, and supply chains. It also warned that for low-margin consumables (e.g. syringes, catheters), applying 5 % GST without robust refund mechanisms could aggravate the inverted duty structure.

Piyush Goyal, Commerce and Industry Minister (government side comment)

The Commerce and Industry Minister has publicly urged all manufacturing and supply-chain players to ensure that the benefits from reduced GST are passed on to the end consumer, warning against profiteering.

What This Means for Patients, Providers & Manufacturers
Patient & Provider Impact

Treatment costs for many diagnoses could drop, especially for chronic and diagnostic services that deploy devices and consumables.

Health insurance coverage becomes more attractive, potentially drawing more people into preventive and managed care models.

Diagnostic uptake may rise as affordability improves, thereby enhancing early detection and care continuum.

Manufacturing & Atmanirbhar Bharat

Lower taxation on inputs, finished devices and diagnostics strengthens the case for scaling domestic production and reducing reliance on imports.

Incentives to invest in R&D, capacity expansion and quality compliance may intensify, especially among MSME medtech players.

However, smooth implementation (timely refunds, clarity in classification, and import-duty alignment) will be critical to sustain competitiveness.

Key Risks & Calls to Action

Refund and input credit mechanisms must function seamlessly to prevent cash-flow blockages for manufacturers.

Classification clarity is essential to avoid litigation or ambiguity for borderline products.

Transition support (especially for smaller firms) is needed for packaging, labeling and regulatory realignment.

Monitoring & enforcement should ensure that price benefits reach patients, not just permitted trade margins.